A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma

Trial Profile

A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Citarinostat (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Acetylon Pharmaceuticals; Celgene Corporation
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 26 Jul 2018 to 29 Jun 2018.
    • 02 Oct 2017 Planned primary completion date changed from 20 Mar 2018 to 20 Feb 2018.
    • 12 Jun 2017 Planned End Date changed from 1 Apr 2017 to 26 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top